Evidence map›Paper›PMID 42461571›Full record

ArticlePulmonary therapy2026

Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial.

Doreen Addrizzo-Harris, James D Chalmers, Stefano Aliberti, Pierre-Régis Burgel, Brian M Morrissey, Xiangmin Zhang, Chunpeng Fan, Melanie Lauterio, Sebastian Fucile, Dianne Griffis and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04594369 (A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04594369 phase3completednot on this map

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study

TypeinterventionalSponsorInsmed IncorporatedRan2020 to 2024Enrolled1,767ConditionsNon-Cystic Fibrosis BronchiectasisArmsBrensocatib 10 mg, Brensocatib 25 mg, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Doreen Addrizzo-HarrisGrossman School of Medicine, New York University, 550 1st Avenue, New York, NY, 10016-6402, USA. Doreen.Addrizzo@nyulangone.org.
James D ChalmersRadcliffe Department of Medicine, University of Oxford, Oxford, UK.
Stefano AlibertiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Pierre-Régis BurgelHôpital Cochin and Cystic Fibrosis National Reference Center, Service de Pneumologie, AP-HP and Université Paris-Cité, Inserm U1016-Institut Cochin, Paris, France.
Brian M MorrisseyDivision of Clinical Internal Medicine, UC Davis Health, Sacramento, CA, USA.
Xiangmin ZhangInsmed Incorporated, Bridgewater, NJ, USA.
Chunpeng FanInsmed Incorporated, Bridgewater, NJ, USA.
Melanie LauterioInsmed Incorporated, Bridgewater, NJ, USA.
Sebastian FucileInsmed Incorporated, Bridgewater, NJ, USA.
Dianne GriffisInsmed Incorporated, Bridgewater, NJ, USA.
Ariel TeperInsmed Incorporated, Bridgewater, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the ASPEN trial, brensocatib, a dipeptidyl peptidase 1 inhibitor, significantly reduced the burden of pulmonary exacerbations versus placebo in participants with bronchiectasis. A prespecified subgroup analysis evaluated the efficacy and safety of brensocatib in participants of Asian race with bronchiectasis from ASPEN.

methodsParticipants with confirmed bronchiectasis and a history of exacerbations in the 12 months before screening [adults (18-85 years), ≥ 2; adolescents (12- < 18 years), ≥ 1] received once-daily brensocatib (10 or 25 mg) or matching placebo for 52 weeks (adults, 1:1:1; adolescents, 2:2:1). Efficacy endpoints included annualized exacerbation rate, time to first exacerbation, and change at 52 weeks in post-bronchodilator (BD) forced expiratory volume (FEV) in 1 s (post-BD FEV

resultsOverall, 191 participants were of Asian race (n = 63, brensocatib 10 mg; n = 64, brensocatib 25 mg; n = 64, placebo). Brensocatib 10 mg and brensocatib 25 mg significantly reduced the annualized exacerbation risk (both by ~ 60%; p = 0.0005 and p = 0.0012, respectively) and prolonged the time to first exacerbation (hazard reduced by ~ 55%; p = 0.0039 and 0.0082, respectively) versus placebo. Brensocatib 25 mg significantly reduced post-BD FEV

conclusionsIn participants of Asian race, brensocatib 10 mg and 25 mg reduced the burden of pulmonary exacerbations, and the 25-mg dose reduced lung function decline and improved patient-reported symptoms versus placebo. The efficacy and safety of brensocatib in participants of Asian race were largely consistent with the overall ASPEN population, with select outcomes showing numerically greater benefit, although ASPEN was not powered to detect treatment differences in prespecified subgroup analyses. CLINICALTRIALS: GOV IDENTIFIER: NCT04594369.

Indexed as

Asian raceASPEN trialBrensocatibBronchiectasisDPP1 inhibitorLung functionPatient-reported outcomesPulmonary exacerbations

Identifiers

PMID42461571
PMCPMC13569732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.